Circulating MiR-92a, MiR-143 and MiR-342 in Plasma Are Novel Potential Biomarkers for Acute Myeloid Leukemia

Overview

Journal Int J Mol Cell Med

Specialty Genetics

Date 2017 Sep 12

PMID 28890884

Citations 25

Authors

Amr Rafat Elhamamsy

Muhammad Suleiman El Sharkawy

Ahmed Farouk Zanaty

Mohammed Ahmed Mahrous

Ahmed Ezzat Mohamed

Eslam Ahmed Abushaaban

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that function as post-transcriptional gene expression regulators. The expression profiling of miRNAs has already entered into cancer clinics as diagnostic and prognostic biomarkers to assess tumor initiation, progression and response to treatment in cancer patients. Recent studies have opened the way for the use of circulating miRNAs as non-invasive diagnosis and prognosis of Acute myeloid leukemia (AML). The aim of this study was to identify plasma miR-92a, miR-143 and miR-342 expression signatures in AML patients to introduce new markers for establishing AML diagnosis and prognosis. Blood samples were collected from 65 AML patients and 50 controls. The expression of three target miRNAs (miR-92a, miR-143 and miR-342) was measured using quantitative real-time PCR method. Plasma levels of miR-92a, miR-143 and miR-342 were significantly lower in AML patients in comparison with control group. Receiver operator characteristic (ROC) analysis revealed that the sensitivity and specificity values of miR-92a were 81.5% and 94%, respectively, with a cut-off value of 0.704. The sensitivity and specificity values of miR-143 were 87.7% and 80%, respectively, with a cut-off value of 0.65. The sensitivity and specificity values of miR-342 were 75.4% and 90%, respectively, with a cut-off value of 0.479. Our findings suggest that plasma miR-92a, miR-143 and miR-342 could be promising novel circulating biomarkers in clinical detection of AML.

Citing Articles

Use of extracellular vesicle microRNA profiles in patients with acute myeloid leukemia for the identification of novel biomarkers.

Kang K, Gim J, Hong S, Kim H, Choi Y, Park J PLoS One. 2024; 19(8):e0306962.

PMID: 39178208 PMC: 11343415. DOI: 10.1371/journal.pone.0306962.

miRNA-143 expression is associated with inflammation and time of exposure to amniotic fluid in experimental gastroschisis.

Diniz A, Gualberto I, Lima L, Cirino M, Murakami R, Ishikiriama B Clinics (Sao Paulo). 2023; 78:100311.

PMID: 38008037 PMC: 10757286. DOI: 10.1016/j.clinsp.2023.100311.

Liquid Biopsy in Head and Neck Cancer: Its Present State and Future Role in Africa.

Temilola D, Adeola H, Grobbelaar J, Chetty M Cells. 2023; 12(22).

PMID: 37998398 PMC: 10670726. DOI: 10.3390/cells12222663.

Targeting of AKT1 by miR-143-3p Suppresses Epithelial-to-Mesenchymal Transition in Prostate Cancer.

Armstrong L, Willoughby C, McKenna D Cells. 2023; 12(18).

PMID: 37759434 PMC: 10526992. DOI: 10.3390/cells12182207.

Exosomal miR92a Promotes Cytarabine Resistance in Myelodysplastic Syndromes by Activating Wnt/β-catenin Signal Pathway.

Li H, Xie C, Lu Y, Chang K, Guan F, Li X Biomolecules. 2022; 12(10).

PMID: 36291656 PMC: 9599242. DOI: 10.3390/biom12101448.

References

Kroh E, Parkin R, Mitchell P, Tewari M . Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010; 50(4):298-301. PMC: 4186708. DOI: 10.1016/j.ymeth.2010.01.032. View

Shen J, Zhang Y, Fu H, Wu D, Zhou H . Overexpression of microRNA-143 inhibits growth and induces apoptosis in human leukemia cells. Oncol Rep. 2014; 31(5):2035-42. DOI: 10.3892/or.2014.3078. View

Godley L, Cunningham J, Dolan M, Huang R, Gurbuxani S, McNerney M . An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol. 2011; 38(2):215-24. PMC: 5591437. DOI: 10.1053/j.seminoncol.2011.01.003. View

Wang H, Wu J, Meng X, Ying X, Zuo Y, Liu R . MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1. Carcinogenesis. 2011; 32(7):1033-42. DOI: 10.1093/carcin/bgr081. View

Zhang H, Cai X, Wang Y, Tang H, Tong D, Ji F . microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol Rep. 2010; 24(5):1363-9. DOI: 10.3892/or_00000994. View

Marcucci G, Mrozek K, Radmacher M, Garzon R, Bloomfield C . The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood. 2010; 117(4):1121-9. PMC: 3056468. DOI: 10.1182/blood-2010-09-191312. View

Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976; 33(4):451-8. DOI: 10.1111/j.1365-2141.1976.tb03563.x. View

Li Q, Liu L, Li W . Identification of circulating microRNAs as biomarkers in diagnosis of hematologic cancers: a meta-analysis. Tumour Biol. 2014; 35(10):10467-78. DOI: 10.1007/s13277-014-2364-4. View

Mazeh H, Mizrahi I, Ilyayev N, Halle D, Brucher B, Bilchik A . The Diagnostic and Prognostic Role of microRNA in Colorectal Cancer - a Comprehensive review. J Cancer. 2013; 4(3):281-95. PMC: 3584841. DOI: 10.7150/jca.5836. View

10.

Kirschner M, Kao S, James Edelman J, Armstrong N, Vallely M, van Zandwijk N . Haemolysis during sample preparation alters microRNA content of plasma. PLoS One. 2011; 6(9):e24145. PMC: 3164711. DOI: 10.1371/journal.pone.0024145. View

11.

Li X, Chen Y, Josson S, Mukhopadhyay N, Kim J, Freeman M . MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. PLoS One. 2013; 8(8):e70987. PMC: 3739799. DOI: 10.1371/journal.pone.0070987. View

12.

Khasawneh M, Abdel-Wahab O . Recent discoveries in molecular characterization of acute myeloid leukemia. Curr Hematol Malig Rep. 2014; 9(2):93-9. DOI: 10.1007/s11899-014-0200-y. View

13.

Ohyashiki K, Umezu T, Yoshizawa S, Ito Y, Ohyashiki M, Kawashima H . Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma. PLoS One. 2011; 6(2):e16408. PMC: 3044711. DOI: 10.1371/journal.pone.0016408. View

14.

Xie X, Liu H, Wang M, Ding F, Xiao H, Hu F . miR-342-3p targets RAP2B to suppress proliferation and invasion of non-small cell lung cancer cells. Tumour Biol. 2015; 36(7):5031-8. DOI: 10.1007/s13277-015-3154-3. View

15.

Pereira D, Rodrigues P, Borralho P, Rodrigues C . Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2012; 18(5-6):282-9. DOI: 10.1016/j.drudis.2012.10.002. View

16.

Garofalo M, Croce C . microRNAs: Master regulators as potential therapeutics in cancer. Annu Rev Pharmacol Toxicol. 2010; 51:25-43. DOI: 10.1146/annurev-pharmtox-010510-100517. View

17.

Wieser R, Scheideler M, Hackl H, Engelmann M, Schneckenleithner C, Hiden K . microRNAs in acute myeloid leukemia: expression patterns, correlations with genetic and clinical parameters, and prognostic significance. Genes Chromosomes Cancer. 2009; 49(3):193-203. DOI: 10.1002/gcc.20740. View

18.

Stahlhut C, Slack F . MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications. Genome Med. 2013; 5(12):111. PMC: 3978829. DOI: 10.1186/gm516. View

19.

Batliner J, Buehrer E, Fey M, Tschan M . Inhibition of the miR-143/145 cluster attenuated neutrophil differentiation of APL cells. Leuk Res. 2011; 36(2):237-40. DOI: 10.1016/j.leukres.2011.10.006. View

20.

Ha T . MicroRNAs in Human Diseases: From Lung, Liver and Kidney Diseases to Infectious Disease, Sickle Cell Disease and Endometrium Disease. Immune Netw. 2012; 11(6):309-23. PMC: 3275699. DOI: 10.4110/in.2011.11.6.309. View